中国中医科学院西苑医院,北京市海淀区西苑操场1号,100091
zhyq992@163.com
收稿:2026-01-11,
修回:2026-03-27,
录用:2026-02-28,
纸质出版:2026-07-02
移动端阅览
李兴榕,董海航,张会芹等.从“脾失散精、肾失化气”论治瘦型代谢相关脂肪性肝病[J].中医杂志,2026,67(13):1446-1450.
LI Xingrong,DONG Haihang,ZHANG Huiqin,et al.Treating Lean Metabolic Associated Fatty Liver Disease from the Perspective of "Spleen Failing to Disperse Essence and Kidney Failing to Transform Qi"[J].Journal of Traditional Chinese Medicine,2026,67(13):1446-1450.
李兴榕,董海航,张会芹等.从“脾失散精、肾失化气”论治瘦型代谢相关脂肪性肝病[J].中医杂志,2026,67(13):1446-1450. DOI: 10.13288/j.11-2166/r.2026.13.015.
LI Xingrong,DONG Haihang,ZHANG Huiqin,et al.Treating Lean Metabolic Associated Fatty Liver Disease from the Perspective of "Spleen Failing to Disperse Essence and Kidney Failing to Transform Qi"[J].Journal of Traditional Chinese Medicine,2026,67(13):1446-1450. DOI: 10.13288/j.11-2166/r.2026.13.015.
认为瘦型代谢相关脂肪性肝病呈现“形瘦而肝肥”状态。以“脾失散精、肾失化气”之病机演变为切入点,以脾肾亏虚为本,肝郁痰瘀为标,系统论治本病。脾虚失运,精微不布,为脂浊壅塞之始;肾失气化,精血不充,为形体失养之根;终致肝郁失疏,精微逆乱,痰瘀凝于肝络。三脏功能失调,构成气、血、津、液、精等物质代谢紊乱的病理基础。治疗上应遵循“养正则积自除”,分三法论治:健脾化湿,取四逆散合二陈平胃散复中焦运化,使精微归于正途;补肾化浊,予金匮肾气丸合一贯煎填补下元,使精髓得充、浊邪得化;疏肝化瘀,以六君子汤合消脂清肝汤条达气血之滞,以截断病势。三法共奏扶正祛邪之效,使精归正化,脂浊得消。
It is considered that lean metabolic associated fatty liver disease (MAFLD) is characte-rized by a state of "lean body but fatty liver". From the perspective of the pathomechanism evolution of "spleen failing to disperse essence, while kidney failing to transform
qi
", the disease is systematically treated under the principle that spleen and kidney deficiency as the root and liver constraint with phlegm stasis as the branch. Spleen deficiency with impaired transformation and transportation leads to failure in the distribution of refined substances, initiating lipid turbidity accumulation and obstruction. Kidney dysfunction in
qi
transformation results in insufficient essence and blood, forming the root of bodily malnourishment. Over time, this further gives rise to liver constraint and loss of dispersing function, disorder in the mov
ement of essential substances, and congealing of phlegm and stasis within hepatic collaterals. The dysfunction of three organs including spleen, kidney and liver constitutes the pathological basis of metabolic disturbances involving
qi
, blood, body fluids and essence. Treatment should follow the principle of "nourishing the healthy
qi
leads to spontaneous resolution of pathogenic accumulation", with three approaches. First, fortifying the spleen and eliminating dampness, using
Sini Powder
(四逆散) and
Erchen Pingwei Powder
(二陈平胃散) to restore the transport and transformation function of the middle
jiao
(焦), thereby guiding essential substances back to their proper physiological pathways. Second, tonifying the kidney and resolving turbidity, using
Jinkui Shenqi Pill
(金匮肾气丸) and
Effective Integration Decoction
(一贯煎) to replenish the lower
jiao
, promoting the restoration of essence and the transformation of turbid pathogen. Third, soothing the liver and resolving stasis, using
Liujunzi Decoction
(六君子汤) and
Xiaozhi Qinggan Decoction
(消脂清肝汤) to vent
qi
and blood stagnation, thereby interrupting disease progression. Together, these three methods reinforce healthy
qi
while eliminating pathogen, facilitating the restoration of proper essence transformation and the resolution of lipid turbidity.
Song Z , Bu S , Sang S , et al . The active components of traditional Chinese medicines regulate the multi-target signaling pathways of metabolic dysfunction-associated fatty liver disease [J]. Drug Des Devel Ther , 2025 , 19 : 2693 - 2715 . DOI: 10.2147/DDDT.S514498 http://dx.doi.org/10.2147/DDDT.S514498 .
Huang S , Bao Y , ZHANG N , et al . Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis [J]. Endocrine , 2024 , 85 ( 1 ): 134 - 141 .
Wongtrakul W , Charatcharoenwitthaya N , Charatcharoenwitthaya P . Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: an updated meta-analysis [J]. Ann Hepatol , 2024 , 29 ( 3 ): 101288 .
Huo Z , Chen Y , Huang Y , et al . Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts [J]. Gut , 2026 , 75 ( 4 ): 772 - 785 .
Younes R , Govaere O , Petta S , et al . Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? [J]. Gut , 2022 , 71 ( 2 ): 382 - 390 .
Cheah M C C , Crane H , George J . Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis [J]. Hepatol Int , 2025 , 19 ( 3 ): 607 - 618 .
中国中西医结合学会消化系统疾病专业委员会 . 非酒精性脂肪性肝病中西医结合诊疗专家共识(2025年) [J]. 中国中西医结合消化杂志 , 2025 , 33 ( 4 ): 339 - 350 .
周志佳 , 李新月 , 郑超 , 等 . 代谢相关脂肪性肝病肝纤维化的中医药治疗进展 [J]. 临床肝胆病杂志 , 2025 , 41 ( 10 ): 1968 - 1974 .
赛俊婷 , 李秀惠 . 脂肪肝中医证候学研究进展 [J]. 临床肝胆病杂志 , 2024 , 40 ( 10 ): 1929 - 1932 .
由智夫 , 杨玲珑 , 刘桐 , 等 . 苓桂术甘汤治疗非酒精性脂肪肝成分与机制的研究进展 [J]. 中华中医药学刊 , 2026 , 44 ( 4 ): 190 - 195 .
徐金铭 , 王芳芳 , 曹迪 , 等 . 柴胡及其药对的药理研究进展 [J/OL]. 中华中医药学刊 .( 2025-07-29 )[ 2026-03-01 ]. https://link.cnki.net/urlid/21.1546.R.20250728. 1644.012 https://link.cnki.net/urlid/21.1546.R.20250728.1644.012 .
陈宇 , 周芸湄 , 李丹 , 等 . 黄精的现代药理作用研究进展 [J]. 中药材 , 2021 , 44 ( 1 ): 240 - 244 .
董海航 , 涂钰莹 , 李兴榕 , 等 . 消脂清肝汤调控铁死亡治疗代谢障碍相关性脂肪性肝病的作用机制 [J]. 中国实验方剂学杂志 , 2026 , 32 ( 6 ): 109 - 119 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号